多西紫杉醇对蒽环类耐药性晚期乳腺癌的疗效分析  

Docetaxel-based combination regimen in the treatment of anthracycline-resistant advanced breast cancer

作　　者：李云霞[1] 刘新兰[1] 王宁菊[1] 

机构地区：[1]宁夏医学院附属医院,宁夏银川750004

出　　处：《宁夏医学杂志》2008年第7期598-599,共2页Ningxia Medical Journal

摘　　要：目的观察国产多西紫杉醇(Taxotere,TXT)为主的联合化疗方案治疗蒽环类耐药的晚期乳腺癌的疗效与安全性。方法晚期乳腺癌患者46例,其中21例给予多西紫杉醇联合顺铂(TXT+DDP)方案化疗,17例给予多西紫杉醇联合吡喃阿霉素(TXT+THP)方案化疗,8例给予多西紫杉醇联合米托蒽醌(TXT+MIT)方案化疗。21天为1周期,2周期后评价疗效,有效患者治疗4周期以上。结果46例均可评价疗效,完全缓解(CR)4例(8.7%),部分缓解(PR)22例(47.9%),稳定(SD)18例(39.1%),进展(PD)2例(4.3%),总有效率(CR+PR)为56.6%,中位肿瘤进展时间(TTP)为7.5个月。结论以多西紫杉醇为主的联合化疗可以作为治疗蒽环类耐药性晚期乳腺癌的补救方案。Objective To evaluate the efficacy and safety of combination chemotherapy with Docetaxel （Taxotere, TXT） based regimen in the treatment of anthracycline - resistant advanced breast cancer. Methods Forty - six patients with anthracycline - resistant advanced breast cancer were treated with docetaxel - containing combination regimens. The docetaxel based regimens included docetaxel/cisplatin for 21 cases, docetaxel/perarubicin for 17 cases, docetaxel/mitoxantrone for 8 cases. The regimen was repeated every 21 days and the clinical response was assessed after two cycles. The median number of cycles was 3 （range ：2 - 6） cycles. Results CR 4 cases, PR 22 cases, SD 18 cases and PD 2 cases, the overall response rate was 56. 6% with a median time to progression of 7.5 months. One -year survival rate was 71.7%. The main side effects were nausea vomiting and hematologic toxicities, but they were tolerable. There were no any deaths during treatment. Conclusion Docetaxel - based combination regimen has good anti - tumor activity on patients with anthracycline - resistant advanced breast cancer with an acceptable toxicity , and may be a therapeutics alternative after anthracycline regimen has faild.

关 键 词：多西紫杉醇 蒽环类药物 联合化疗 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]